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Abstract
Background. Immunomodulation may represent a potential way to improve surgical outcome. These types of interventions
should be based on detailed knowledge of the underlying mechanisms involved. The aim of the present review is to
summarize some experience on the acute phase response, potential ways of intervention and experiences from critical illness
and HPB disease. Discussion. Mechanisms of the acute phase response are discussed including the individual parameters
and local changes that take part. Mechanisms involved in failure of the gut barrier are presented and include changes in gut
barrier permeability, effects on gut-associated immunocompetent cells, and systemic implications. As examples of HPB
disease, mechanisms of the acute phase response and potential ways of intervention in obstructive jaundice and acute
pancreatitis are discussed. Nutritional pharmacology and lessons learned from immunomodulation and immunonutrition in
critical illness and major abdominal surgery, including upper GI and HPB surgery, are referred to. Overall,
immunomodulation represents a potential tool to improve results but requires a thorough mapping of underlying
mechanisms in order to achieve individualized treatment or prevention based on patients’ specific needs.
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Introduction
Immunomodulation has been suggested as one way of
optimizing the course of surgical patients, both as part
of the perioperative management in elective surgical
patients and in acute disease and critical illness. The
concept has also been included in nutritional manage-
ment and termed immunonutrition. Modulation of
the acute phase response and immune function,
however, requires a detailed knowledge about the
acute inflammatory response and its mechanisms in
order to understand and optimize selective interven-
tion. This review discusses some of the mechanisms
involved in the acute inflammatory response, that
have the potential for intervention. It is understood
that we still lack substantial information in order to
treat and prevent by modulating the immune response
in the most optimal and ‘‘tailored’’ fashion. However,
some experience already exists as regards at which
time point and with what agents we potentially can
intervene in different disease processes, and lessons
learned from treatment in critical illness are of value.
Immunomodulation in HPB disease and surgery will
also be discussed.
Surgery and the acute phase response
Major surgery results in an acute phase response
where the magnitude of the response usually corre-
lates with the extent of the surgical trauma. The
surgical intervention also results in a transient im-
munosuppression and potential alterations in gastro-
intestinal tract function. In the normal situation, these
alterations are restored within a few days unless
complications occur [1].
The immune response caused by the surgical
intervention may be followed by an excessive inflam-
matory response and paralysis of cell-mediated im-
munity. This effect of major surgery could be
responsible for the increased susceptibility to subse-
quent septic complications [2]. It has been shown that
laparoscopic surgery results in diminished tissue
trauma as compared with open surgery [3]. Decreased
surgical trauma by minimal invasive surgery together
with, for example, optimal pain control, early enteral
nutrition and mobilization, brought together as
‘‘facilitated’’ or ‘‘fast track surgery’’, probably di-
minishes the operative stress and acute inflammatory
response (Figure 1) [4].
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The acute phase and inflammatory response follow-
ing surgical trauma in critical illness seem to depend
on the net of the pro- and anti-inflammatory re-
sponses that occur simultaneously. In critical illness
and after major surgical trauma in general the overall
response seems to be a hyperinflammatory response,
which could include the development of the systemic
inflammatory response syndrome (SIRS) that might
proceed to the development of ‘‘early’’ multiple organ
dysfunction syndrome (MODS). Later on during the
course of disease, a net hypoinflammatory state may
occur, sometimes termed the compensatory anti-
inflammatory response syndrome (CARS). During
this phase, a supervening infection or sepsis could
further impair the condition and contribute to the
development of ‘‘late’’ MODS [5].
The acute phase response
The acute phase response is the result of the action of
pro- and anti-inflammatory factors as mentioned
above. A number of pro-inflammatory mediators are
known to play a major role in the complex acute phase
response, among others the intracellular pro-inflam-
matory regulator nuclear factor kappa B (NF-kB), as
well as cytokines like tumor necrosis factor (TNF)k ,
interleukin (IL)-1, IL-6 and IL-8, and platelet activat-
ing factor. Upregulation of various adhesion mole-
cules is also involved in the acute phase response and
participates in the potential development of organ
failure. Contributory factors also include endotoxin,
oxygen free radicals, nitric oxide and histamine as well
as enzymes like phospholipase A2, especially when
released from neutrophils that have migrated through
the endothelial barrier into the tissues of various
organs, thereby causing tissue injury and organ fail-
ure. Overall, the magnitude of the acute phase
response and the cytokine and mediator release seems
to correlate well with the potential development of
systemic complications and remote organ failure, as
has been shown both experimentally and in the
clinical setting [6/9].
Local challenges may be followed by systemic
effects, where the changes that occur merely depend
on the magnitude of the local injury. Furthermore,
local preventive and therapeutic interventions may
also contribute to a normalization of the systemic
response. For example, a gut-pulmonary axis been
described where local injury to the gut will affect the
lungs [10/12]. Similarly, a gut-liver axis has been
described in which obstructive jaundice negatively
affects gut barrier function and activation of host
immune function [13].
Gut barrier failure and sepsis
The gastrointestinal tract has been called ‘‘the un-
drained abscess’’ of multiple organ failure [14]. The
gut barrier has mostly been considered as a defense
against permeability and the permeation of bacteria
and toxins normally contained within the intestinal
lumen. However, gut barrrier failure has been shown
not only to represent an increase in intestinal perme-
ability and translocation, but also concerns the
activation of immunocompetent cells within the gut
wall and associated lymph nodes. Overall, mucosa-
associated lymphoid tissue (MALT) and gut-asso-
ciated lymphoid tissue (GALT) probably represent
one of our largest immunological ‘‘organs’’ [15]. The
combination of increased barrier permeability and gut
inflammation may end up in the interaction between
polymorphonuclear leukocytes and the endothelial
lining, potentially resulting in remote organ dysfunc-
tion, e.g. in the lungs (Figure 2).
Figure 1. Surgery and the immune response.
Figure 2. Gut barrier failure includes both an increase in intestinal
permeability and a gut inflammatory state. MALT, mucosa-
associated lymphoid tissue; GALT, gut-associated lymphoid tissue;
PMN, polymorphonuclear leukocytes.
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The complexicity underlying gut barrier failure is
illustrated when summarizing some pathophysiologi-
cal mechanisms involved in intestinal barrier failure in
acute experimental pancreatitis (Figure 3) [15]. As
can be seen, the complexicity in gut barrier dysfunc-
tion is substantial and involves a number of factors
that individually represent potential targets for both
preventive and therapeutic measures [15,16].
Why no magic bullets modulating the acute
phase response?
A number of interventions have been tried individu-
ally in the clinical setting, based on successful experi-
mental findings. Regrettably, the overall result has
been a failure in demonstrating a beneficial clinical
outcome with these types of interventions. Reasons
for this might be the fact that there seems to be a
limited window for potential therapeutic intervention,
especially in critical illness, with complex mechanisms
from the very onset and a rapid progression of the
disease. Thus, treatment attempts at blocking various
individual pro-inflammatory responses have failed.
Moreover, we still lack a proper mapping of the actual
course of the acute phase response, knowledge which
could represent a basis for obtaining a more tailored
and individualized type of treatment.
Potential interventions include gut protective stra-
tegies, modulation of SIRS, endothelial barrier dys-
function and MODS and the potential role of
immunonutrition, in which case the route of admin-
istration and the addition of individual supplements
with beneficial effects (‘‘nutritional pharmacology’’)
have to be addressed.
Concerning gut protection, the permeability as well
as the gut inflammatory response have been ad-
dressed. The importance of luminal nutrition has to
be emphasized, as enterocytes depend on glutamine
to a large extent and colonocytes depend on short-
chain fatty acids as energy source [17]. No parenteral
supplementation will thus fully compensate for the
lack of luminal nutrition and absence of these specific
‘‘nutrients’’.
Modulation of SIRS, endothelial barrier dysfunc-
tion and MODS may be achieved by for example the
administration of anti-oxidants. Other potential ways
of obtaining this could be by blocking pro-inflamma-
tory cytokines, the administration of platelet activat-
ing factor antagonists, antibodies against adhesion
molecules or agents binding endotoxin. Immunonu-
trition and the route of administration of nutrition
have to be addressed, where the importance of gut
luminal nutrition should be emphasized. Factors to
consider are patients’ basic nutritional requirements
and additives if, for example, malnutrition, severe
catabolism, complications, intensive care treatment,
etc., exist. The administration of probiotics or syn-
biotics could also be of benefit. The role of key
nutrients, often as supplements to nutritional formu-
las, on the acute inflammatory response, immune
competence and gastrointestinal function has to be
further investigated.
Obstructive jaundice–effects on immune
function and outcome
Obstructive jaundice has been reported to be asso-
ciated with an impaired immune function, including
both the systemic and local defense. Alterations have
been reported in gut barrier function, as well as the
existence of endotoxemia. Overall, an increase in the
incidence of postoperative complications including
sepsis and infection has been seen in obstructive
jaundice [18,19]. Host defense in subjects with ob-
structive jaundice is influenced in multiple ways. The
overall reticuloendothelial system (RES) seems to be
impaired and Kupffer cell function is altered. An
impaired cellular immunity, including both the fixed
reticuloendothelial system and macrophages has been
reported, as well as a decrease in natural killer cell
Figure 3. Interactive mechanisms underlying the development of intestinal barrier failure in acutew experimental pancreatitis. RES,
reticuloendothelial system.
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activity. Biliary obstruction has also been associated
with an increase in cytokine release, including TNFa,
IL-6 and IL-8, and upregulation of adhesion mole-
cules.
Biliary obstruction results in an increase in intest-
inal permeability, upregulation of HLA-DR expres-
sion on enterocytes and GALT, suggesting an
immune activation. There also seems to be an
increase in the acute phase response and in circulating
anti-endotoxin core antibodies. Following internal
biliary drainage, a normalization of intestinal perme-
ability occurs [20].
Additional surgery exaggerates the impaired gut
barrier function and activation of host immune
function seen in patients with obstructive jaundice,
implying caution in order to minimize the risk of
developing systemic complications [13]. The endo-
toxemia noted in biliary obstruction is considered to
be due to a number of coinciding changes including
an increase in intestinal permeability and a lack of bile
flow to the gastrointestinal tract, with concomitant
absence of bile salt neutralization of endotoxin. A
decrease in the elimination of endotoxin could also be
due to altered Kupffer cell function. Altogether this
favours the occurrence of endotoxemia in jaundice
and can be summarized as disturbances in the home-
ostasis of the suggested gut-liver axis [21]. A number
of interventions have been tried to improve immune
function in obstructive jaundice. For example, pre-
operative lactulose administration in biliary obstruc-
tion seems effective in experimental biliary obstruction
[22,23]. Lactulose was also of benefit when adminis-
tered together with deoxycholate for the prevention
of postoperative renal dysfunction in jaundiced pa-
tients [24]. Mechanisms explaining the effect of
lactulose may be inactivation of gut-derived endotoxin
and endoxotin-induced TNF production [25,26].
The impaired RES function in obstructive jaundice
is restored after internal biliary drainage but the
recovery phase is prolonged. Also, intestinal perme-
ability slowly recovers after internal biliary drainage.
For both alterations, a period of up to 5 weeks seems
to be required to regain normal function [20,27].
This prolonged recovery has been a contributing
factor to questioning the routine use of preoperative
biliary stenting in jaundiced patients [28]. Preoperative
biliary drainage has even been reported to increase
complications, including infectious complications, in-
tra-abdominal abscess formation and postoperative
death, in patients subjected to pancreaticoduo-
denectomy [29].
Immunomodulation has been tried in obstructive
jaundice. Experimentally, the administration of an
immunostimulating compound (muramyl dipeptide)
improved RES recovery in jaundiced rats treated with
internal biliary decompression [30,31]. Immunomo-
dulation by the use of muramyl tripeptide phospha-
tidyl-ethanolamine inhibited bacterial translocation,
probably by activation of mucosal macrophages in
experimental biliary obstruction [32].
Acute pancreatitis and the inflammatory
response
Acute pancreatitis is a pronounced pro-inflammatory
condition, especially in fulminant cases. Central
mechanisms include the existence of ischemia and
reperfusion injury and increased endothelial barrier
permeability. Experimentally, treatment with, for
example, platelet activating factor inhibitors, antibo-
dies against adhesion molecules and tromboxane A2,
has been effective against microcirculatory and en-
dothelial barrier permeability derangements [33,34].
Oxygen free radicals play a crucial pathophysiolo-
gical role, especially during the early stages of acute
pancreatitis and are produced in response to ischemia/
reperfusion. Antioxidants have partly been effective in
experimental acute pancreatitis, decreasing the mag-
nitude of endothelial barrier dysfunction in remote
organs. Clinical data supporting an effect by anti-
oxidant administration alone is, however, lacking
[35/37].
Immunomodulation may also be achieved by the
administration of steroids. Beneficial effects have been
reported in experimental pancreatitis following ad-
ministration of steroids [38] but this has not been
reproduced clinically [39]. The use of glucocorticoids
may, however, be of value, as part of a multimodal
treatment strategy, as they suppress the inflammatory
response, potentially by the inhibition NF-kB, a
dominant intracellular regulator of the pro-inflamma-
tory response [40,41]. Experimentally, specific inhibi-
tion of NF-kB has improved outcome [42/44].
Cytokine release, including IL-6 and IL-8, has been
identified as an early predictor of severity in acute
pancreatitis [45/47]. Treatment with IL-10 and
selective inhibition of IL-1 b and IL-8 have been
shown to be of benefit in experimental acute pancrea-
titis [48/50]. The expression of adhesion molecules is
central in the development of endothelial barrier
dysfunction, regulates transmigration of neutrophils
and concomitant development of organ dysfunction.
Experimentally, treatment with antibodies against
adhesion molecules like ICAM-1 and PECAM-1 has
been effective [51/54]. Combining various agents in a
‘‘multimodal treatment’’ directed against various
pathophysiological mechanisms in acute pancreatitis
has been tried experimentally. The combination of the
broad-acting antioxidant N-acetylcysteine, the PAF
inhibitor lexipafant and monoclonal antibodies
against the adhesion molecule PECAM-1 was effec-
tive when administered in animals with ongoing
organ failure in a model of taurodeoxycholate-
induced acute pancreatitis. By this treatment, the
acute phase response and organ dysfunction de-
creased, and gut barrier failure and translocation
could be prevented [55]. Clinical evidence for the
Immunomodulation in surgical practice 119
effectiveness of this type of ‘‘cocktail regimen’’ is still
not available.
Anticoagulation and anti-inflammation
Attention has recently been paid to the anti-inflam-
matory properties possessed by various antico-
agulating agents. Activated protein C blunts the
anti-inflammatory response to sepsis [56] and the
use of recombinant activated protein C has been
shown to reduce mortality in severe sepsis [57]. Anti-
inflammatory properties have also been proposed
when inhibiting other factors of the coagulation
cascade, like inhibition of tissue factor pathway
inhibitor, factor Xa and factor VII [58,59]. This field
of potential intervention is presently under investiga-
tion and the future will tell us about the value of this
strategy, taking the increased risk of bleeding into
account.
Nutritional pharmacology
Arginine
The amino acid arginine possesses cytoprotective
effects in ischemia and reperfusion and can form
nitric oxide, citrulline, ornithine, growth factors, etc.,
and exerts numerous beneficial effects on the immune
system. Arginine induces secretion of numerous
hormones like pituitary growth hormone, insulin-like
growth factor IgF-1, insulin, vasopressin, catechola-
mines, and somatostatin. Arginine also inhibits NF-
kB translocation and decreases the release of IL-6,
TNFa, IL-18, blocks adhesion molecules and inhibits
lipid peroxidation [60].
Glutamine
Glutamine is a non-essential glycogenic amino acid
and the preferred fuel for lymphocytes, enterocytes,
and neutrophils. Glutamine also improves neutrophil,
lymphocyte, and intestinal function [61]. This amino
acid also maintains a normal GALT function and
respiratory immunity [60].
Omega 3 Fatty Acids
Omega 3 polyunsaturated fatty acids (PUFA) repre-
sent essential fatty acids that possess immunomodu-
lating effects due to their rapid incorporation into cell
membranes. Thereby, they have influence on mem-
brane stability, fluidity, cell mobility, and intra-cellu-
lar signaling pathways, as well as gene expression and
cell differentiation. Omega 3 fatty acids are claimed to
provide protection against infection [62]. Omega 3
fatty acids regulate the immune response by increas-
ing membrane fluidity, introducing free radical lipid
peroxide and by providing precursors in eicosanoid
metabolism.
Nucleotides
Immunosuppression may partly be caused by nucleo-
tide restriction. T-cell-dependent antibody production
and lymphocyte function also seem to depend on
nucleotide supplementation [63].
Lessons learned from immunomodulation and
immunonutrition in critical illness and in
association with major surgery
High-dose parenteral glutamine supplementation was
followed by a reduction in infectious complications
and shortened hospital stay in surgical patients and
reduced complications and mortality in critically ill
patients [64]. Glutamine-containing parenteral nutri-
tion in critically ill ICU patients unable to receive
enteral nutrition improved survival as evaluated after
6 months and reduced hospital costs per survivor
[65]. A glutamine-containing enteral feed in the ICU
reduced costs per survivor by 30% [66].
As mentioned above, the use of activated protein C
reduces mortality in patients with severe sepsis [57].
The use of low-dose steroids decreases mortality in
patients with septic shock and proven adrenalin
insufficiency [67]. Intensive insulin therapy, main-
taining ‘‘normal’’ glucose levels, reduced mortality in
intensive care, especially deaths due to multiple organ
failure in patients with a proven septic focus [68].
Perioperative omega 3 fatty acids downregulate the
inflammatory response, diminish postoperative im-
munosuppression and shorten postoperative intensive
care. Furthermore, the incidence of severe infections
is reduced [69].
Immunonutrition (including arginine, glutamine,
nucleotides, and omega 3 fatty acids) decreases
infectious complications and the length of hospital
stay in the critically ill, and especially in surgical
patients. There does not, however, seem to be any
effect of immunonutrition on mortality [70/74]. An
important observation in a recent review is that
mortality tends to increase in a subgroup of critically
ill patients, especially when using products other than
those high in arginine [75]. The reason for this is to be
speculated upon but further emphasis may be directed
at a more tailored type of immunomodulation, taking
the actual immune function of the individual patient
into consideration.
Perioperative immunonutrition in upper GI and
HPB surgery
Preoperative immunonutrition for 5 days has been
reported to improve outcome, including an improved
immunometabolic response, a decreased infection
rate, and reduced treatment costs of complications.
There seems to be no additional benefit of post-
operative prolongation of the immunonutrition
[76,77].
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In acute pancreatitis, the use of a platelet-activating
factor antagonist initially seemed promising with a
decrease in the incidence of organ failure and organ
failure score [78,79], while later studies could not
confirm the beneficial effects of lexipafant alone in
acute pancreatitis [80,81].
In acute pancreatitis, early enteral nutrition seems
feasible and reduces costs (at least of the nutritional
supply), reduces septic complications, and the in-
flammatory response [82/85]. Overall, these studies
have limitations due to a small number of included
patients, a delay prior to initiation of the enteral
nutrition, varying severity of pancreatitis, and a distal
tube positioning. The supplementation with lacto-
bacilli and fibers in early enteral nutrition reduced the
incidence of pancreatic sepsis and the need for
surgical intervention in patients with prognostic
severe acute pancreatitis [86].
For pancreatic cancer, the condition seems to be
associated with a frequent pro-inflammatory response
with increases in, for example, CRP levels. A pre-
dominant problem in patients with irresectable pan-
creatic cancer, or recurrence after radically attempted
resection, is cancer cachexia which seems to depend
on the acute phase response [87]. A positive effect on
the acute phase response, cancer-associated cachexia
and quality of life has been reported following the
administration of EPA (eicosapentaenoic acid, an
omega 3 PUFA) [88]. Further support for a pro-
inflammatory response in pancreatic cancer is the
finding of an increased expression of cyclooxygenase
(COX)-2 in pancreatic cancer and that resting energy
expenditure decreased, implying a reduction in acute
phase protein production, with ibuprofen administra-
tion in pancreatic cancer patients [89,90].
Conclusion and future aspects
In general, it seems that a limited window for
intervention exists for modulation of the acute in-
flammatory response due to its complexity. Multiple
mediators are involved and thereby a multimodal
approach seems reasonable. From a nutritional point
of view, emphasis should be put on the importance of
enteral nutrition. Preoperative immunomodulation is
probably becoming more established and could be
offered as an oral formula. Additional specific nu-
trients and compounds are awaited, the indications
for which should be based on the knowledge derived
from a detailed mapping of the dynamics of the acute
phase response, rendering possibilities for a future
tailored and individualized treatment.
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